Tecovirimat Synthesis Routes for Higher Yield and Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for orthopoxvirus infections, such as smallpox and monkeypox, face challenges including poor bioavailability, dose-limiting toxicity, resistance to cidofovir, and unspecific antiviral compounds with undesirable side effects, necessitating the development of more effective and safer therapeutic options.
Innovation Solution
A series of synthetic routes are developed to produce ST-246, a compound effective against orthopoxviruses, involving reactions with tert-butyl carbazate, maleic anhydride, cycloheptatriene, and 4-(trifluoromethyl)benzoyl chloride, with specific conditions and solvents to enhance yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cidofovir is used to treat orthopoxvirus infections, then antiviral efficacy is achieved, but dose-limiting nephrotoxicity occurs
Solution Approach 1:
The patent extracts and removes the harmful nephrotoxic property from the antiviral treatment by replacing cidofovir with ST-246, which provides similar antiviral efficacy against orthopoxviruses without the dose-limiting nephrotoxicity. This substitution eliminates the harmful factor while preserving the beneficial antiviral effect.
Solution Approach 2:
The patent employs a small molecule compound (ST-246) that can be administered orally and does not accumulate to toxic levels, unlike cidofovir which requires intravenous administration and causes cumulative nephrotoxicity. The new compound provides effective treatment without the long-term harmful accumulation.
2Reliability
If vaccination is used to prevent orthopoxvirus infections, then protective immunity is achieved, but adverse events occur frequently
Solution Approach 1:
The patent extracts the protective immunity function from vaccination while removing the associated adverse events by developing ST-246 as an alternative therapeutic. This small molecule provides effective treatment against orthopoxvirus infections without the frequent adverse events (1:5000) and serious complications (1:300,000) associated with vaccinia-based vaccines.
Solution Approach 2:
The patent introduces ST-246 as an intermediary therapeutic agent that achieves the protective effect without requiring live virus vaccination. This small molecule inhibitor of viral egress serves as a safe alternative that bridges the need for protection against orthopoxviruses while avoiding the harmful side effects of traditional vaccination.
3Object-affected harmful factors
If smallpox vaccine program was terminated, then safety concerns are reduced, but individuals are no longer immune to smallpox infection
Solution Approach 1:
The patent introduces ST-246 as a new therapeutic intermediary that restores protection against orthopoxvirus infections without requiring resumption of the smallpox vaccine program. This small molecule provides the necessary immunity protection while maintaining the safety benefits of not using live vaccinia virus, particularly for immunocompromised individuals.
Solution Approach 2:
The patent changes the therapeutic approach from live virus vaccination to a small molecule inhibitor of viral egress. This parameter change in the mode of intervention provides equivalent protection against orthopoxviruses while eliminating the safety concerns associated with terminated vaccination programs, allowing treatment of immunocompromised populations.
4Adaptability or versatility
If recombinant forms of poxvirus are developed, then research capabilities are enhanced, but potential for causing disease in vaccinated animals increases
Solution Approach 1:
The patent employs ST-246, a stable small molecule compound, as a therapeutic countermeasure against recombinant poxviruses. This provides a reliable treatment option that addresses the safety concern of recombinant virus research while preserving research capabilities, as ST-246 can effectively treat infections from both wild-type and recombinant orthopoxviruses.
Data Source
AI summary
Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopox virus. The methods proceed via the synthetic intermediate 9, which has the following formula.